Effects of quetiapine extended release on sleep and quality of life in midlife women with major depressive disorder

Depression during midlife years may lead to significant sleep disturbances and adversely impact quality of life (QOL). In this report, we examined the effects of treatment with quetiapine extended release (XR), 150–300 mg/day, on sleep and QOL in 23 midlife women with major depressive disorder (MDD)...

Full description

Saved in:
Bibliographic Details
Published in:Archives of women's mental health 2013-02, Vol.16 (1), p.83-85
Main Authors: Frey, Benicio N., Haber, Erika, Mendes, Gustavo C. D., Steiner, Meir, Soares, Claudio N.
Format: Article
Language:English
Subjects:
Adult
Analysis
Antipsychotic Agents - administration & dosage
Antipsychotic Agents - therapeutic use
Canada
Complications and side effects
Delayed-Action Preparations
Depressive Disorder, Major - drug therapy
Depressive Disorder, Major - psychology
Dibenzothiazepines - administration & dosage
Dibenzothiazepines - therapeutic use
Dosage and administration
Dose-Response Relationship, Drug
Drug therapy
Female
Humans
Major depressive disorder
Medicine
Medicine & Public Health
Menopause
Mental depression
Middle age
Middle Aged
Psychiatry
Psychological aspects
Psychotherapy
Quality of life
Quality of Life - psychology
Quetiapine
Quetiapine Fumarate
Short Communication
Single-Blind Method
Sleep
Sleep - drug effects
Sleep disorders
Sleep Wake Disorders - drug therapy
Sleep Wake Disorders - psychology
Treatment Outcome
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Depression during midlife years may lead to significant sleep disturbances and adversely impact quality of life (QOL). In this report, we examined the effects of treatment with quetiapine extended release (XR), 150–300 mg/day, on sleep and QOL in 23 midlife women with major depressive disorder (MDD). Quetiapine XR improved subjective sleep distress, overall sleep parameters, and sleep-related QOL, ultimately leading to significant improvement in menopause-related QOL. While larger, controlled trials are still awaited, these preliminary results are encouraging and suggest that quetiapine XR may be a useful tool in treating symptomatic midlife women with MDD.
ISSN:1434-1816
1435-1102
DOI:10.1007/s00737-012-0314-y